Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937841 | 0.83 | TGFBR1 (0.48) | CDC7DBF4CDK2CDK4NPC1 | |
| SCHEMBL3661249 | 0.79 | KDM4E (0.49) | CDC7DBF4CDK2CDK4RAB9A | |
| SCHEMBL3232125 | 0.77 | PIK3CA (0.43) | CDC7DBF4CDK2CDK4CCNE1 | |
| SCHEMBL13358975 | 0.76 | PIK3CA (0.45) | CDC7DBF4CDK2CDK4CCNE1 | |
| SCHEMBL3669248 | 0.75 | PIK3CA (0.46) | CDC7CDK2CDK4RAB9ACCNE1 | |
| SCHEMBL3663885 | 0.75 | CDK4 (0.43) | CDC7DBF4CDK2CDK4RAB9A | |
| SCHEMBL3237122 | 0.75 | PIK3CA (0.52) | CDK2CDK4RAB9ACCNE1PIK3CD | |
| SCHEMBL3232487 | 0.75 | PIK3CA (0.51) | CDK2CDK4RAB9ACCNE1PIK3CD | |
| SCHEMBL3162020 | 0.75 | PIK3CA (0.53) | CDK2CDK4RAB9ACCNE1PIK3CD | |
| SCHEMBL3240860 | 0.74 | PIK3CA (0.45) | CDC7DBF4CDK2CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-8476268-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | CDC7 365/4885DBF4 4346/4885CDK2 220/4885 |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | CDC7 365/4885DBF4 4346/4885CDK2 220/4885 |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PDPK1, MTOR, PIK3C2A | CDC7 454/4885DBF4 4149/4885CDK2 173/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | CDC7 1341/4885DBF4 4217/4885CDK2 241/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | CDC7 971/4885DBF4 4062/4885CDK2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.